Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Influenza virus infections lead to thousands of deaths worldwide annually and billions of dollars economic burden. Despite continuing advances in our understanding of the immune evasion mechanism, the disease remains one of the foremost threat for human being. Traditional vaccines (attenuated and inactivated) mainly provide protection by inducing virus neutralizing antibodies, targeting ever changing surface antigens: Haemagultinin (HA) and Neuraminidase (NA). Due to genetic shift and immune selection pressure, prevalence of circulating influenza virus subtypes changes every year. Therefore, mismatch between circulating strain and vaccine strain can critically affect the success rate of these conventional flu vaccines, and requires continuous monitoring of circulating influenza virus subtypes and change in the vaccine formulations accordingly. The collective limitations of existing flu vaccines urgently call for the development of a novel universal vaccines that might provide the required protective immunity to a range of influenza virus subtypes. New approaches are being investigated mainly targeting conserved regions of flu proteins. Some of these approaches include universally conserved epitopes of HA, nucleoprotein (NP), capsid protein (M1) and ion channel protein (M2) that induced strong immune responses in animal models. Some attention and progress appears to be focused on vaccines based on the M2 ectodomain (M2e) employing a variety of constructs, adjuvants and delivery systems, including M2e-hepatitis B core antigen, flagellin constructs, and virus-like particles (VLP). Animal studies with these M2e candidate vaccines demonstrated that these vaccine candidates can prevent severe illness and death but not infection, which may pose difficulties in both the evaluation of clinical efficacy and approval by the regulatory authorities. VLP vaccines appear to be promising, but still are mostly limited to animal studies. The discovery and development of new and improved vaccines have been greatly facilitated by the application of new technologies. The use of nucleic acid-based vaccines, to combine the benefits of in-situ expression of antigens with the safety of inactivated and subunit vaccines, has been a key advancement. Upon their discovery more than 20 years ago, nucleic acid vaccines promised to be a safe and effective mean to mimic immunization with a live organism vaccine, particularly for induction of T cell immunity. In addition, the manufacturing of nucleic acid-based vaccines offered the potential to be relatively simple, inexpensive and generic. Reverse Vaccinology and in-silico designing of vaccines are very innovative approaches and being considered as future of vaccines. Furthermore, various immuno-therapeutic agents also being developed to treat and minimize immuno-pathological damage in patients suffering from life threatening complications. For the treatment of such pathological conditions, various novel approaches such as administration of immune suppressive cytokines, blocking co-stimulatory signals or activating co-inhibitory signal of T cell activation, are being tested both in lab and clinics. The Research Topic on influenza virus vaccine and therapeutics will give an insight in to the current status and future scope of these new innovative approaches and technologies. Moreover, these new methods will also serve as a reference tool for the development of future vaccines against several other pathogens.

T Cell Immunity --- Neutralization antibody --- Influenza Virus --- Vaccine --- Immunotherepy --- adjuvants

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Influenza virus infections lead to thousands of deaths worldwide annually and billions of dollars economic burden. Despite continuing advances in our understanding of the immune evasion mechanism, the disease remains one of the foremost threat for human being. Traditional vaccines (attenuated and inactivated) mainly provide protection by inducing virus neutralizing antibodies, targeting ever changing surface antigens: Haemagultinin (HA) and Neuraminidase (NA). Due to genetic shift and immune selection pressure, prevalence of circulating influenza virus subtypes changes every year. Therefore, mismatch between circulating strain and vaccine strain can critically affect the success rate of these conventional flu vaccines, and requires continuous monitoring of circulating influenza virus subtypes and change in the vaccine formulations accordingly. The collective limitations of existing flu vaccines urgently call for the development of a novel universal vaccines that might provide the required protective immunity to a range of influenza virus subtypes. New approaches are being investigated mainly targeting conserved regions of flu proteins. Some of these approaches include universally conserved epitopes of HA, nucleoprotein (NP), capsid protein (M1) and ion channel protein (M2) that induced strong immune responses in animal models. Some attention and progress appears to be focused on vaccines based on the M2 ectodomain (M2e) employing a variety of constructs, adjuvants and delivery systems, including M2e-hepatitis B core antigen, flagellin constructs, and virus-like particles (VLP). Animal studies with these M2e candidate vaccines demonstrated that these vaccine candidates can prevent severe illness and death but not infection, which may pose difficulties in both the evaluation of clinical efficacy and approval by the regulatory authorities. VLP vaccines appear to be promising, but still are mostly limited to animal studies. The discovery and development of new and improved vaccines have been greatly facilitated by the application of new technologies. The use of nucleic acid-based vaccines, to combine the benefits of in-situ expression of antigens with the safety of inactivated and subunit vaccines, has been a key advancement. Upon their discovery more than 20 years ago, nucleic acid vaccines promised to be a safe and effective mean to mimic immunization with a live organism vaccine, particularly for induction of T cell immunity. In addition, the manufacturing of nucleic acid-based vaccines offered the potential to be relatively simple, inexpensive and generic. Reverse Vaccinology and in-silico designing of vaccines are very innovative approaches and being considered as future of vaccines. Furthermore, various immuno-therapeutic agents also being developed to treat and minimize immuno-pathological damage in patients suffering from life threatening complications. For the treatment of such pathological conditions, various novel approaches such as administration of immune suppressive cytokines, blocking co-stimulatory signals or activating co-inhibitory signal of T cell activation, are being tested both in lab and clinics. The Research Topic on influenza virus vaccine and therapeutics will give an insight in to the current status and future scope of these new innovative approaches and technologies. Moreover, these new methods will also serve as a reference tool for the development of future vaccines against several other pathogens.

T Cell Immunity --- Neutralization antibody --- Influenza Virus --- Vaccine --- Immunotherepy --- adjuvants

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Nowadays, more and more innovative and great entrepreneurs decide to take action and to launch their company. However, it is not always easy for those lonely SMEs to stand out from the crowd and some companies, naturally, encounter difficulties to do so. It is particularly the case for companies from the biotech sector which is a highly competitive environment.

Realising my internship at AmplyCell which is in a young and promising company from the biotech sector, the purpose of this thesis is to provide the thinking about the creation of a strategic platform for biotech companies presenting synergies in the same value chain. This report must answer if the implementation of an alliance, in which AmplyCell would belong to provide its technology and develop its activity, is viable and interesting.

The approach to do so is divided in 3 phases. First, a qualitative study is led to understand how existing platforms and alliances are currently working to seek inspiration. Then, a quantitative study is conducted through the help of a survey directed to potential customers in order to understand the needs of the market. A final research is conducted again on potential clients for a deeper understanding of the results of the survey and also on potential partners to get their personal views regarding this partnership implementation.

Searches were successful. This kind of platform usually leads to consortium agreement which is a written document in which all members define the rules of the partnership, the way those rules are defined is discussed in the thesis. This report also identifies the ideal target for the platform as well as some future prospects to ensure continuity of this one and to be always one step ahead of competition. Regarding potential partners, the interest is global as they strongly believe there is no interest to stay alone when it is well known that unity makes strength.

To conclude, create such a platform is not an easy task. Even with the progress already realised, it takes a lot of time to achieve this with the search for partners, negotiations, first steps, etc. But the doubt is now raised regarding the feasibility and the potential that represents the creation of this strategic platform.

Biotech sector --- Antibody market --- Consortium --- Strategic platform --- Alliance --- partnership --- Implementation --- Qualitative study --- Quantitative study --- Survey --- Target --- Customers --- Partners --- Members --- Sciences économiques & de gestion > Marketing --- Sciences du vivant > Biotechnologie

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Autophagy in Current Trends in Cellular Physiology and Pathology is addressed to one of the fundamental molecular mechanisms - autophagy- evolutionarily adopted by cells for processing of unnecessary or malfunctioned constituents and shaping intracellular structures, adjusting them to environmental conditions, aging, disease, neoplasia, and damages over their life period. Particular attention is paid to autophagy-mediated barrier processes of selective sequestration and recycling of impaired organelles and degradation of invading microorganisms, that is, the processes sustaining intrinsic resistance to stress, tissue degeneration, toxic exposures, and infections. The presented topics encompass personal experience and visions of the chapter contributors and the editors; the book chapters include a broad analysis of literature on biology of autophagy.

Phagocytosis. --- Cytology. --- Autophagy. --- Cell biology --- Cellular biology --- Biology --- Cells --- Antigen-antibody reactions --- Endocytosis --- Immune response --- Immunology --- Phagosomes --- Pinocytosis --- Reticulo-endothelial system --- Tuftsin --- Autophagic vacuoles. --- Autophagocytosis --- Life Sciences --- Microbiology --- Genetics and Molecular Biology --- Cytology --- Biochemistry

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

This book reviews the emerging studies of synthetic immunology, including the development and regeneration of immune cells, immune organ development and artificial regeneration, and the synthetic approach towards understanding human immune system. Immunology has developed rapidly over the last 50 years through the incorporation of new methods and concepts in cell and molecular biology, genetics, genomics and proteomics. This progress is the result of works by many excellent researchers all over the world. Currently, immunological research has accumulated detailed knowledge on basic mechanisms of immunity and is in the process to change medical practices. Yet, due to the enormous complexity of the immune system, many aspects on the regulation and function of this system remain unknown. Synthetic biology uses gain-of-function rather than loss-of-function approaches. The goals of synthetic biology can be described in a simple phrase “rebuild, alter, and understand," namely, to rebuild minimal functional systems using well-defined parts from nature and then to perturb the system to understand its working principles. Given the richness of accumulated knowledge in molecular and cellular mechanisms of the immune system, we now begin adapting the concepts of synthetic biology to immunology. An immune response is a spatiotemporal phenomenon occurring at a given time and at a specialized place in the body. One goal of synthetic immunology is to reconstruct artificial microenvironments for better understanding of an immune response. We hope this yet-to-be-experimental approach of synthetic immunology and the compilation of this book will aid our further understanding of the immune system and future devising the tools to manipulate the immune system for therapy and prevention of the diseases.

Medicine. --- Immunology. --- Systems biology. --- Biomedical engineering. --- Biomedicine. --- Systems Biology. --- Biomedical Engineering. --- Immune response. --- Immunotechnology. --- Antibody engineering --- Immunological engineering --- Industrial immunology --- Biotechnology --- Immunology --- Biological models. --- Biomedical Engineering and Bioengineering. --- Clinical engineering --- Medical engineering --- Bioengineering --- Biophysics --- Engineering --- Medicine --- Models, Biological --- Immunobiology --- Life sciences --- Serology --- Computational biology --- Bioinformatics --- Biological systems --- Molecular biology